Interim Report, 1 January – 30 September 2013*
Q3 2013 (July-September) Remaining Group operations, excluding Cross Pharma · Net turnover totalled SEK 80.2 million (SEK 36.6 m), SEK 43.6 million (EUR 5 m) of which represented milestone payments. · The profit/loss after tax was SEK -10.7 million (SEK -56.2 m). · Basic and diluted earnings per share totalled SEK -0.34 (SEK -1.80). · The cash flow from operating activities amounted to SEK -5.2 million (SEK -39.1 m), while liquid assets and short-term investments totalled SEK 337.7 million (SEK 356.6 m) at the end of the period. Interim period (January-September) Remaining